← Eichor
Study identifier: NCT07399665 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

Condition: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · Asthma  ·  Sponsor: AstraZeneca

PhaseN/A
Planned participants110
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

ARES is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who have initiated tezepelumab (no more than 4 weeks before inclusion) for treatment of CRSwNP (with or without comorbid asthma).

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center  ·  1-877-240-9479  ·  information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (11)

Research SiteKazan', RussiaRecruiting
Research SiteKemerovo, RussiaNot Yet Recruiting
Research SiteKrasnoyarsk, RussiaRecruiting
Research SiteMoscow, RussiaRecruiting
Research SiteMoscow, RussiaNot Yet Recruiting
Research SiteRostov-on-Don, RussiaRecruiting
Research SiteRyazan, RussiaRecruiting
Research SiteSaint-Petesburg, RussiaRecruiting
Research SiteSaint-Petesburg, RussiaNot Yet Recruiting
Research SiteUlyanovsk, RussiaRecruiting
Research SiteYekaterinburg, RussiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07399665